Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan.
Intern Med. 2022 Nov 15;61(22):3449-3452. doi: 10.2169/internalmedicine.0257-22. Epub 2022 Sep 6.
Coronavirus disease 2019 (COVID-19) has spread worldwide since 2019, and mRNA vaccines for the disease have been rapidly delivered to limit the severity of infection. However, while these vaccines are effective in reducing the morbidity and severity of the disease, some patients develop severe adverse drug reactions and new-onset autoimmune phenomena, such as myocarditis, thrombosis with thrombocytopenia, and vasculitis. In addition, some patients develop arthritis following vaccination, including rheumatoid arthritis (RA). We herein report a case of new-onset seropositive RA following COVID-19 mRNA vaccination. Although tests for rheumatoid factor and anti-cyclic citrullinated peptide antibody had been negative three years before vaccination, the patient developed seropositive RA following COVID-19 mRNA vaccination.
自 2019 年以来,2019 年冠状病毒病(COVID-19)已在全球范围内传播,用于该疾病的 mRNA 疫苗已迅速投放市场,以限制感染的严重程度。然而,尽管这些疫苗可有效降低疾病的发病率和严重程度,但一些患者出现严重的药物不良反应和新出现的自身免疫现象,如心肌炎、伴血小板减少的血栓形成和血管炎。此外,一些患者在接种疫苗后会出现关节炎,包括类风湿关节炎(RA)。本文报告了一例 COVID-19 mRNA 疫苗接种后新发的血清阳性 RA 病例。尽管在接种疫苗前三年,类风湿因子和抗环瓜氨酸肽抗体检测均为阴性,但该患者在 COVID-19 mRNA 疫苗接种后出现血清阳性 RA。